Furthermore, TMZ administration in the morning extended this survival to a 6-month elevated overall survival in MGMT-methylated GBM patients compared to the MGMT-methylated GBM patients who received TMZ in the evening (Damato et al., 2021). This evidence concerns the gene MGMT and glioblastoma.